10 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
|
20103010 Biotechnology |
Other subject |
10 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies présentera des données complémentaires issues de l'étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans et discutera de l'avenir de l'EPIT lors du congrès annuel 2026 de l'AAAAI
|
20103010 Biotechnology |
Other subject |
09 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
|
20103010 Biotechnology |
Other subject |
09 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities
|
20103010 Biotechnology |
Other subject |
05 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
|
20103010 Biotechnology |
Other subject |
05 Feb 2026
22:30 CET |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 janvier 2026
|
20103010 Biotechnology |
Other subject |
17 Jan 2026
00:11 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
|
20103010 Biotechnology |
Other subject |
17 Jan 2026
00:11 CET |
DBV TECHNOLOGIES |
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
|
20103010 Biotechnology |
Other subject |
12 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
|
20103010 Biotechnology |
Other subject |
12 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
|
20103010 Biotechnology |
Other subject |
07 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
|
20103010 Biotechnology |
Other subject |
07 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
|
20103010 Biotechnology |
Other subject |
05 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
|
20103010 Biotechnology |
Other subject |
05 Jan 2026
22:00 CET |
DBV TECHNOLOGIES |
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
|
20103010 Biotechnology |
Other subject |
16 Dec 2025
22:05 CET |
DBV TECHNOLOGIES |
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
|
20103010 Biotechnology |
Other subject |
16 Dec 2025
22:05 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
|
20103010 Biotechnology |
Other subject |
02 Dec 2025
22:00 CET |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
|
20103010 Biotechnology |
Other subject |
02 Dec 2025
22:00 CET |
DBV TECHNOLOGIES |
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
|
20103010 Biotechnology |
Other subject |
12 Nov 2025
05:50 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides
|
20103010 Biotechnology |
Other subject |
12 Nov 2025
05:50 CET |
DBV TECHNOLOGIES |
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
|
20103010 Biotechnology |
Other subject |
04 Nov 2025
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
|
20103010 Biotechnology |
Other subject |
04 Nov 2025
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
|
20103010 Biotechnology |
Other subject |
03 Nov 2025
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
|
20103010 Biotechnology |
Other subject |
03 Nov 2025
22:30 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
|
20103010 Biotechnology |
Other subject |
03 Nov 2025
22:25 CET |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025
|
20103010 Biotechnology |
Other subject |
03 Nov 2025
22:25 CET |
DBV TECHNOLOGIES |
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
|
20103010 Biotechnology |
Other subject |
30 Oct 2025
21:30 CET |
DBV TECHNOLOGIES |
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
|
20103010 Biotechnology |
Other subject |
30 Oct 2025
21:30 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration
|
20103010 Biotechnology |
Other subject |
30 Oct 2025
08:00 CET |
DBV TECHNOLOGIES |
DBV Technologies participe au congrès scientifique annuel de l'ACAAI
|
20103010 Biotechnology |
Other subject |
30 Oct 2025
08:00 CET |
DBV TECHNOLOGIES |
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
|
20103010 Biotechnology |
Other subject |
29 Oct 2025
23:47 CET |
DBV TECHNOLOGIES |
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
|
20103010 Biotechnology |
Other subject |
29 Oct 2025
23:47 CET |
DBV TECHNOLOGIES |
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
|
20103010 Biotechnology |
Other subject |
28 Oct 2025
21:25 CET |
DBV TECHNOLOGIES |
DBV Technologies publie ses résultats financiers du troisième trimestre 2025
|
20103010 Biotechnology |
Other subject |
28 Oct 2025
21:25 CET |
DBV TECHNOLOGIES |
DBV Technologies Reports Third Quarter 2025 Financial Results
|
20103010 Biotechnology |
Other subject |
06 Oct 2025
23:02 CEST |
DBV TECHNOLOGIES |
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
|
20103010 Biotechnology |
Other subject |
06 Oct 2025
23:02 CEST |
DBV TECHNOLOGIES |
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
|
20103010 Biotechnology |
Other subject |
18 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies annonce la démission d’un membre de son Conseil d’administration
|
20103010 Biotechnology |
Other subject |
18 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies Announces Resignation of Board Member
|
20103010 Biotechnology |
Other subject |
05 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
|
20103010 Biotechnology |
Other subject |
05 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
|
20103010 Biotechnology |
Other subject |
03 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
|
20103010 Biotechnology |
Other subject |
03 Sep 2025
22:30 CEST |
DBV TECHNOLOGIES |
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
|
20103010 Biotechnology |
Other subject |
01 Aug 2025
22:05 CEST |
DBV TECHNOLOGIES |
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
|
20103010 Biotechnology |
Other subject |
01 Aug 2025
22:05 CEST |
DBV TECHNOLOGIES |
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025
|
20103010 Biotechnology |
Other subject |
29 Jul 2025
22:17 CEST |
DBV TECHNOLOGIES |
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
|
20103010 Biotechnology |
Other subject |
29 Jul 2025
22:17 CEST |
DBV TECHNOLOGIES |
DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
|
20103010 Biotechnology |
Other subject |
29 Jul 2025
22:08 CEST |
DBV TECHNOLOGIES |
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
|
20103010 Biotechnology |
Other subject |
29 Jul 2025
22:08 CEST |
DBV TECHNOLOGIES |
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
|
20103010 Biotechnology |
Other subject |
28 Jul 2025
22:30 CEST |
DBV TECHNOLOGIES |
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
|
20103010 Biotechnology |
Other subject |
28 Jul 2025
22:30 CEST |
DBV TECHNOLOGIES |
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
|
20103010 Biotechnology |
Other subject |